Tocilizumab for the treatment of rheumatoid arthritis (rapid review of technology appraisal guidance 198)

NICE technology appraisals [TA247] Published date:

This guidance updates and replaces NICE technology appraisal 198 (published in August 2010).

NICE recommends tocilizumab, taken with a drug called methotrexate, as a possible treatment for some people with rheumatoid arthritis (see below).

Who can have tocilizumab?

You should be able to have tocilizumab if:

Why has NICE said this?

NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE recommended tocilizumab in these circumstances because it works well and its cost is justified after other drugs have been tried.

Get involved